Meet the Team

Management

Chris Fashek

Chairman and CEO

linkedinChrisTieChris Fashek is Spiracur’s Chairman of the Board of Directors and was appointed President and Chief Executive Officer of the company in April 2014. Prior to this, he was Chairman of the Board and a Director of Systagenix Wound Management, Ltd. Systagenix Wound Management represents key wound care brands including SilverCel®, Promogran® and Prisma®. Previously, Mr. Fashek served as President and Vice Chairman of Kinetic Concepts, Inc. (KCI) USA, the leader in the NPWT wound care category. Prior to that, Mr. Fashek managed businesses in the pharmaceutical and consumer product markets for Sterling Drug, a division of Eastman Kodak in the United States and internationally.

Mr. Fashek currently serves as Director of the IDN Summit, World Craniofacial Foundation, and other commercial and charitable boards. He received his MBA from Fairleigh Dickinson University and a BA from Upsala College.

Gary Restani

Vice Chairman

linkedinGaryTieGary Restani is a proven international executive with over 35 years of worldwide experience in the medical device industry. As the President of ConvaTec, a Bristol Myers-Squibb Company, Gary developed a high performance management team, which helped ConvaTec to become the leading wound and ostomy company with worldwide revenue of over $1 billion.More recently, he served as President & COO of Hansen Medical where he directed the company from late stage development to early stage commercialization and first year revenues.

Gary also has over 11 years of experience in the orthopedic sector, having held divisional President roles with both Smith & Nephew and Zimmer. Gary led Zimmer Europe/MEA through a significant turnaround, contributing to Zimmer’s growth. He has served on the board of ADVAMED (1997-2006) as well as the leadership board of the Cleveland Clinic’s Center for Digestive diseases (2000-2006). Gary currently serves on the board of Corpak Medsystems and DFine Inc. He attended Sir George Williams University and Loyola University in Canada. He received a certificate from Dartmouth College for completing the Tuck School of Business flagship General Management Executive Program.

Steven Van Dick

Vice President of Finance and Administration & Chief Financial Officer

linkedinSteveTieSteve Van Dick is a proven financial executive with over 20 years of experience in corporate financial management with several medical device and medical imaging companies. Prior to joining Spiracur in January 2011, Steve served as Chief Financial Officer of Hansen Medical, where he was responsible for completing the initial public offering and building strong relationships with Wall Street analysts and fund managers. Prior to this, Steve served as Chief Financial Officer of a number of companies, including CryoVascular Systems, Inc., Protogene Laboratories, Inc., CardioThoracic Systems, Inc. and Perclose, Inc.

Steve brings broad business experience in financial operations, which will help Spiracur as it transitions from start-up to a fast growing commercial entity. Steve holds a BS from San Jose State University and a MBA from Santa Clara University. In addition, he is a Certified Public Accountant.

Kenton Fong, MD

Founder & Chief Scientific Officer

linkedin_5292KentonTieDr. Fong has more than 15 years of biomedical research experience with Stanford University, Chang Mai University, and the University of California, San Francisco. His research spans a wide range of disciplines, from tissue engineering and developmental biology to health policy and new technology development, resulting in over 50 publications and numerous national speaking engagements.

Dr. Fong has undergraduate and graduate degrees in Biology and Psychology from Stanford University. He earned his medical degree from the University of California, San Francisco School of Medicine and completed a post-doctoral research fellowship in tissue engineering and developmental biology at Stanford University School of Medicine. Dr. Fong was trained in Plastic and Reconstructive Surgery at Stanford University where he also served as Chief Resident.

Larry Hu

Vice President of R&D & Operations

linkedinLarryTieLarry Hu has over 17 years of experience in the medical device industry in product development, manufacturing, and operations roles. His most recent position was Director of Operations at CryoVascular Systems which was acquired by Boston Scientific in 2005.

Larry was also Director of Product Development at CardioThoracic Systems, a minimally invasive surgical company, which was acquired by Guidant. He began his career at Cordis/Johnson & Johnson where he held various product development and manufacturing engineering and management positions. Larry graduated from the University of Michigan, Ann Arbor with a BS in Mechanical Engineering.

Yousuf Mazhar

Vice President of Business Development and Health Policy

linkedinYousufTieYousuf Mazhar has over 15 years of experience in Investment Banking, Venture Capital, and Healthcare.  Prior to Spiracur Yousuf was with De Novo Ventures leading investments in medical devices and diagnostics, including Spiracur.  Prior to that Yousuf was with Kaiser Permanente in their Venture Capital Group and on their Competitive Intelligence Team.  He led primarily health service and healthcare IT investments and co-developed the firms internal M&A practice group.  Yousuf began his career on Wall Street with UBS Investment Banking and later joined the Global Technology Mergers and Acquisitions Group at JP Morgan and its predecessor H&Q.

Yousuf holds a BS and an MBA with Honors from the Wharton School of the University of Pennsylvania, and a Master’s in BioTechnology from the University of Pennsylvania School of Engineering and Applied Science.

Dane Shackleford

Vice President of Global Sales and Marketing

linkedinDaneTieDane Shackleford joined Spiracur to help build an organization with a culture of entrepreneurial thinking and a mantra of always conducting business with the patient’s best interests in mind. Dane is a seasoned senior sales and marketing executive with over 20 years of experience in the medical device industry. He brings over a decade of wound-care-specific experience from industry leader, KCI, where he helped build their negative pressure business while ascending to VP of Sales. In addition to KCI, Dane has held senior management positions in a variety of medical device firms, including GE Healthcare, Labcorp, and Alsius Corporation.

Dane’s innovative leadership style has facilitated the development of high performing sales, clinical, service and marketing teams throughout his career. These teams have ranged in size from 10 individuals to over 100, and the associated revenue growth has ranged from $5M to over $250M.

Debbie White

Senior Director of Human Resources and Corporate Communications

linkedinDebbieDebbie White has over 20 years of experience in the medical device industry.  Prior to joining Spiracur in 2008, Debbie led the human resources and administrative functions for a number of companies including CryoVascular Systems, Inc., Protogene Laboratories, Inc., CardioThoracic Systems, Inc. and CardioVascular Imaging Systems, Inc.

Debbie’s broad background includes system and program development, implementation and management in start-up and early commercial stage companies.  She has been an integral part of the management team for both initial public offerings and corporate acquisitions.  Debbie holds a BA in Sociology from the University of California, Santa Cruz.

Board of Directors

Jeani Delagardelle

Jeani Delagardelle is a managing director of New Leaf Venture Partners, a healthcare technology fund established in August 2005 by the healthcare technology partners of the Sprout Group. Ms. Delagardelle joined Sprout in August 2000 and became General Partner in July 2001. Previously, she was a general partner focused on healthcare investments at Weiss, Peck & Greer Venture Partners. Before joining Weiss, Peck & Greer, Ms. Delagardelle spent 15 years in senior marketing, sales, business development and general manager positions in the healthcare industry. During this time she served as vice president of Global Marketing for Target Therapeutics (acquired by Boston Scientific for $1.1 billion) and held several senior management roles in the Medi-tech division of Boston Scientific. Ms. Delagardelle also served as director of Business Operations for Roche Laboratories and director of Global Marketing for Cell Pro, Inc.

In addition to her work with Spiracur she also serves on the Board of Directors of Access Closure Inc., Direct Flow Medical, Intrinsic Therapeutics, ReShape Medical, Altura Medical and World Heart.

Ms. Delagardelle holds an MBA from the University of California at Irvine and an A.B. from Occidental College.

Chris Fashek

Chris Fashek is Spiracur’s Chairman of the Board of Directors and was appointed President and Chief Executive Officer of the company in April 2014. Prior to this, he was Chairman of the Board and a Director of Systagenix Wound Management, Ltd. Systagenix Wound Management represents key wound care brands including SilverCel®, Promogran® and Prisma®. Previously, Mr. Fashek served as President and Vice Chairman of Kinetic Concepts, Inc. (KCI) USA, the leader in the NPWT wound care category. Prior to that, Mr. Fashek managed businesses in the pharmaceutical and consumer product markets for Sterling Drug, a division of Eastman Kodak in the United States and internationally.

Mr. Fashek currently serves as Director of the IDN Summit, World Craniofacial Foundation, and other commercial and charitable boards. He received his MBA from Fairleigh Dickinson University and a BA from Upsala College.

Rich Ferrari

Rich Ferrari has been a successful CEO of several medical technology companies, both prior to and after co-founding De Novo Ventures in 2000. Following De Novo’s investment in CryoVascular Systems, Mr. Ferrari became CEO, growing the initial 5 person start up team to a company of 20 employees. He was instrumental in developing the clinical and product strategies and hiring the executive team. In 2002, Mr. Ferrari led Paracor Medical, another De Novo portfolio company. He grew the company from 4 to 22 employees, refined the product strategy, raised its Series B financing and hired his replacement CEO. Prior to co-founding De Novo Ventures, he was the co-founder and CEO of CardioThoracic Systems (“CTSI”), a company he led to an initial public offering in only 7 months in 1996. CTSI, the market leader in disposable instruments and systems for performing minimally invasive beating heart bypass surgery, was ultimately acquired by Guidant Corporation in November 1999. Before that, Mr. Ferrari was the CEO of Cardiovascular Imaging Systems (“CVIS”). As CEO, he orchestrated a successful IPO and ultimately sold the company to Boston Scientific Corporation in 1995.

In addition, Mr. Ferrari founded Saratoga Ventures in 1996, a venture capital partnership that has provided seed financing to startup medical technology companies, including Atrionix, Oratec, Enteric Medical, Trivascular, and Endotex. At Saratoga, he was Chairman of Oratec, which was sold in 2001 to Smith & Nephew PLC. Mr. Ferrari also co-founded The Medical Technology Group, which spun out Integrated Vascular Systems, an early stage femoral artery closure company which was sold to Abbott and Angiosense, a needle-free, jet injection, local drug delivery company. Early in his career, Mr. Ferrari held the position of Executive Vice President and General Manager of ADAC Laboratories. He holds a BS degree from Ashland University and an MBA from the University of South Florida.

In addition to Spiracur, Mr. Ferrari sits on the boards of Benvenue, CardioMind, MyoScience, Ovalis, Paracor Medical, Pulmonx, Simpirica, Spinal Kinetics and Spinal Modulation. His prior board involvement includes TriVascular.

Dana Mead

Dana Mead joined Kleiner Perkins Caufield & Byers as a partner in May 2005 to work in the life sciences practice.

For the past 23 years, Mr. Mead’s career has focused on identifying new medical technologies, developing new markets and therapies, and building world-class management teams. He has worked with physician thought leaders around the world representing 10 different medical specialties. At KPCB, Mr. Mead leverages experience gained from his venture-funded, start-up management roles and board participation to support entrepreneurs and innovators dedicated to making a real difference in the lives of millions suffering from life-limiting disease.

Prior to joining KPCB, Mr. Mead was President of Guidant Vascular Intervention, a fully integrated billion dollar division with over 4,500 employees. After joining Guidant in 1992, he held positions of increasing responsibility including: Vice President and General Manager, Cardiac & Vascular Surgery; Vice President and General Manager, Stents, Vascular Intervention Group; President, Japan and A/P Operations based in Tokyo; and Vice President, Corporate Relations and Policy with responsibility for investor relations, corporate communications, corporate marketing and public policy initiatives. Prior to joining Guidant, Mr. Mead worked in various sales and marketing roles at Allergan, Inc. and Johnson & Johnson. A native of Connecticut, he received his Bachelor’s degree from Lafayette College and holds an MBA degree from the University of Southern California. Dana serves on the boards of AesThera, Inc., Corventis, Navigenics, Inc., OtisMed Corporation, Sinexus, Inc., Synvascular, Invuity, Inc., Spinal Modulation, Inspire Medical Systems, Voyage Medical, the California Healthcare Institute (CHI), the Cardiovascular Research Foundation (CRF), and Lucile Packard Children’s Hospital.

Moshe Pinto

After completing his military service in the Israeli Defense Forces, Moshe Pinto enrolled in Tel Aviv University Law School where he earned his LLB. He later practiced law for 3 years as a corporate lawyer at Herzog, Fox, and Neeman, one of Israel’s leading law firms. While at Herzog, Fox, and Neeman, Moshe was elected as the Tel Aviv University representative to the ERASMUS MUNDUS program in law and economics and left Israel for Germany and Italy where he earned a JD and a Masters in Economics.

Upon earning his JD, Moshe was admitted to the Stanford Graduate School of Business where he earned his MBA. During his time at Stanford, Moshe participated at the Stanford Biodesign Innovation program where he teamed up with Dr. Kenton Fong and Dean Hu in the development of the technology around which they formed Spiracur. Moshe served as Spiracur’s CEO from June 2007 to March 2010.

Gary Restani

Gary Restani is a proven international executive with over 35 years of worldwide experience in the medical device industry. As the President of ConvaTec, a Bristol Myers-Squibb Company, Gary developed a high performance management team, which helped ConvaTec to become the leading wound and ostomy company with worldwide revenue of over $1 billion.More recently, he served as President & COO of Hansen Medical where he directed the company from late stage development to early stage commercialization and first year revenues.

Gary also has over 11 years of experience in the orthopedic sector, having held divisional President roles with both Smith & Nephew and Zimmer. Gary led Zimmer Europe/MEA through a significant turnaround, contributing to Zimmer’s growth. He has served on the board of ADVAMED (1997-2006) as well as the leadership board of the Cleveland Clinic’s Center for Digestive diseases (2000-2006). Gary currently serves on the board of Corpak Medsystems and DFine Inc. He received a certificate from Dartmouth College for completing the Tuck School of Business flagship General Management Executive Program.

David B. Singer

David B. Singer is responsible for Maverick’s Private Investments globally. He joined Maverick in 2004 from Oscient Pharmaceutical Corporation, where he was Chairman of the Board.

Mr. Singer is a founder and former CEO of three healthcare companies: Affymetrix, Inc.; Corcept Therapeutics, Inc.; and, Genesoft Pharmaceuticals, Oscient’s predecessor. Mr. Singer currently serves on the boards of several private companies in the fields of healthcare information technology, healthcare delivery, and biotechnology.

Mr. Singer received a B.A. from Yale University and an M.B.A. from Stanford University. He was a Crown Fellow of the Aspen Institute and a member of the Rand Corporation’s Health Advisory Board. He is currently a Sterling Fellow of Yale University, and a director of College Track. In July 2013, Mr. Singer was appointed by the Mayor of San Francisco to be a Health Commissioner and a member of the San Francisco General Hospital Joint Conference Committee.

Investors

Kleiner Perkins Caufield & Byers

Kleiner Perkins Caufield & Byers are committed to helping entrepreneurs build enduring market-changing institutions, defining new business sectors or expanding existing ones. Since 1972, their partners have supported hundreds of entrepreneurs in building over 475 companies, including such household names as Amazon, Sun, Genentech, Intuit, Verisign and Google.

They work tirelessly on behalf of entrepreneurs and share the benefits of their experience to develop new enterprises. Their Relationship Capital creates an informal, far-reaching network to assist entrepreneurs as they learn from one another and build the great businesses of tomorrow.

KPCB is constantly on the lookout for ideas with the promise to invent new business categories or radically alter existing ones. Their passion is for new technologies and new applications of technology that will drive high-impact change.
www.kpcb.com

De Novo Ventures

De Novo Ventures was formed in 2000 by seasoned investors and experienced medical device entrepreneurs who sought to share the lessons learned from a history of successful investing and building successful companies. They believed that their unique combination of skills and perspectives could help entrepreneurs to build companies which would have significant clinical impact and generate superior returns. Seven years later, this belief continues to hold true, demonstrated by our investment success in selected medical device and biotechnology companies.
With $650 million under management, De Novo has made more than 40 investments in medical devices and biotechnology across three funds. We invest in all stages of enterprise development and growth – from early stage to late stage. Our unique background of leading companies as entrepreneurs and operating executives from start to exit enables us to advise entrepreneurs and management teams over the full life cycle of the company.
www.denovovc.com

New Leaf Venture Partners

New Leaf Venture Partners is a leader in healthcare technology venture investing. Their investment professionals bring a unique blend of technological, clinical, and operational experience to their investments. New Leaf works closely with their entrepreneurs to help build successful portfolio companies. They focus primarily on later stage biopharmaceutical products, early stage medical devices, and laboratory infrastructure technologies.

New Leaf currently manages $1.3 billion in assets. This includes their newest fund, New Leaf Ventures II, L.P. which closed with commitments of $450 million in October 2007, New Leaf Ventures I, L.P. and the healthcare technology portfolio of the Sprout Group, one of the oldest U.S. venture capital fund groups.
www.nlvpartners.com

Maverick Capital

Maverick Capital is a global investment firm with offices in New York, San Francisco, London, Hong Kong, Philadelphia and Dallas. With over $11 Billion in assets under management, Maverick’s 50 person investment team seeks to grow and preserve capital for its investors, primarily through a long/short hedged equity strategy. Since the Firm’s inception in 1993, Maverick has strategically invested in private companies that represent disruptive business models or technologies. Maverick actively partners with portfolio company teams through the deployment of its resources and deep fundamental research capabilities to help entrepreneurs build their businesses.
www.maverickcap.com


Back to top